Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
This article was originally published in The Pink Sheet Daily
Executive Summary
“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.
You may also be interested in...
Northfield Labs Eyes First Half 2008 For PolyHeme BLA Submission
The company will seek a priority review for the investigational red blood cell substitute.
Northfield Labs Eyes First Half 2008 For PolyHeme BLA Submission
The company will seek a priority review for the investigational red blood cell substitute.
Northfield Suffers Setback On Phase III PolyHeme Study
Data discrepancies, protocol violations mar preliminary top-line results for experimental blood substitute.